Top 20 Generics Pharma Companies Based on 2021 Total Revenue

Shots: With an increased price range and the lack of accessibility of branded products, the generic version of these products has been established to be more affordable and accessible to patients, providers, and the healthcare system. Therefore, Generic medicines are a bioequivalent substitute for a marketed brand-name drug, developed after the expiry of the patent…

ByPrince GiriOctober 13, 2022

INSIGHTS+

Insights+ Key Biosimilars Events of May 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of May, JSR Life Sciences launches Similis Bio business…

BySenior EditorJune 2, 2022

INSIGHTS+

Insights+ Key Biosimilars Events of March 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of March, Junshi & Mabwell Bioscience’s Junmaikang (biosimilar, adalimumab)…

BySenior EditorApril 7, 2022

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2022

The first quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include Biocon acquired Viatris’ biosimilars assets for ~$3.335B, Stryker signed a definitive agreement to acquire Vocera Communications for ~$3.09B, Biohaven acquire Channel Biosciences for ~$3B The first quarter of the year also showcases regulatory events…

BySenior EditorMarch 31, 2022

INSIGHTS+

Insights+ Key Biosimilars Events of February 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of February, Biocon acquired Viatris’ biosimilars assets for ~$3.335B,…

BySenior EditorMarch 3, 2022

TOP 20

Top 20 Generics Pharma Companies Based On 2020 Revenue

Shots: Generic medicines are the backbone of the healthcare system and are identical to the innovator medicine in strength- effect- dosage form- and route of administration. These are allowed for sale after the patent expiry of the original drugs Our team at PharmaShots has compiled a list of the top 20 generic companies based on…

ByPrince GiriOctober 28, 2021

INSIGHTS+

Insights+ Key Biosimilars Events of July 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of Jul, Viatris & Biocon's Semglee got the US…

BySenior EditorAugust 5, 2021

INSIGHTS+

Insights+ Key Biosimilars Events of March 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of March, Samsung Bioepis Initiated P-I Study of SB17…

BySenior EditorApril 1, 2021

INSIGHTS+

Insights+ Key Biosimilars Events of February 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of Feb, Biocon collaborated with CHAI to expand access…

BySenior EditorMarch 4, 2021

INSIGHTS+

Insights+ Key Biosimilars Events of August 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Mylan with its partner Lupin and Biocon launched Nepexto (biosimilar, etanercept) and Semglee (insulin glargine injection) in Germany & in the US, respectively. Additionally, Formycon and Bioeq planned to initiate P-III MAGELLAN-AMD Trial for its FYB203 (biosimilar,…

BySenior EditorSeptember 3, 2020

Top 20 Generics Pharma Companies Based on 2021 Total Revenue

Insights+ Key Biosimilars Events of May 2022

Insights+ Key Biosimilars Events of March 2022

PharmaShots’ Key Highlights of First Quarter 2022

Insights+ Key Biosimilars Events of February 2022

Top 20 Generics Pharma Companies Based On 2020 Revenue

Insights+ Key Biosimilars Events of July 2021

Insights+ Key Biosimilars Events of March 2021

Insights+ Key Biosimilars Events of February 2021

Insights+ Key Biosimilars Events of August 2020

Contact US

FOLLOW US